GlassScriptPhysician profile
Nicholas A Patellis
NPI 1366582835
$2,254.19
in general payments reported to CMS, 2019-2025
24 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $164 · 2021: $420 · 2022: $660 · 2023: $362 · 2024: $281 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.24 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,034.86 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $166.62 | 2019-2023 | Breztri |
| Otsuka America Pharmaceutical, INC. | $116.45 | 2021-2025 | Rexulti |
| Antares Pharma, INC. | $105.42 | 2019-2023 | Nocdurna, Xyosted, Tlando |
| Irhythm Technologies, INC. | $100.69 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Pfizer INC. | $98.02 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.37 | 2022-2023 | |
| Lilly USA, LLC | $69.64 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $67.50 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $61.13 | 2019-2022 | |
| Lundbeck LLC | $55.67 | 2022-2023 | Vyepti |
| Sanofi-Aventis U.S. LLC | $44.35 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $43.18 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.52 | 2021-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.23 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $20.37 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.40 | 2021 | |
| Abbott Laboratories | $17.61 | 2022 | |
| Astellas Pharma US INC | $17.40 | 2021 | |
| Ibsa Pharma INC. | $16.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.67 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.48 | 2023 | Quviviq |
| Halozyme INC | $13.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Patellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.